Souhaitez-vous accéder aux communiqués récents ?

Hengrui Pharma and Kailera Therapeutics announce clinical data presentations at the American Diabetes Association 86th Scientific Sessions

Felix to lower semaglutide pricing by up to 65% as generic options enter Canada, helping improve affordability for weight management patients.

Novel alternative to GLP-1 drugs: Phase I data demonstrate fat mass reduction, preservation of lean mass, 80% responder rate, and no serious adverse events

Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support

Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially...

Insider conviction, late-stage clinical wins, and platform technologies are converging to reshape biotech/pharma valuations and patient outcomes.

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, announced that it will begin offering...

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions relate

MyFitnessPal launches free GLP-1 Support feature, combining nutrition, medication, reminders, and side effect tracking to boost results and build lasting h

SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...